Sanofi (NASDAQ:SNY) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a report issued on Saturday morning.

A number of other research analysts have also recently weighed in on the stock. Argus upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Finally, BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Up 1.0%

Shares of NASDAQ:SNY opened at $44.66 on Friday. The business has a 50-day moving average price of $43.35 and a 200 day moving average price of $45.52. The company has a market capitalization of $108.28 billion, a price-to-earnings ratio of 12.47, a PEG ratio of 1.14 and a beta of 0.34. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its position in shares of Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock worth $456,956,000 after acquiring an additional 940,342 shares in the last quarter. Morgan Stanley boosted its holdings in Sanofi by 20.4% in the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after purchasing an additional 1,540,271 shares in the last quarter. Invesco Ltd. increased its stake in Sanofi by 5.4% in the fourth quarter. Invesco Ltd. now owns 6,110,874 shares of the company’s stock valued at $296,133,000 after purchasing an additional 313,327 shares during the last quarter. Raymond James Financial Inc. increased its stake in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Sanofi by 29.7% during the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after purchasing an additional 1,168,339 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.